Participant 20: NeuroProof
NeuroProof GmbH, Rostock, Germany
Participant leader: Dr. Olaf Schröder
NeuroProof GmbH offers screening services to analyze and elucidate the complex effects of substances on the functions of the brain and the entire central nervous systems. With these results, the effects of potential drug on the CNS and possible neurotoxic effects can be predicted at an early stage. Thus it is possible to greatly accelerate the development of CNS drugs during the preclinical stage, and to reduce costs.
NeuroProof GmbH is a spin-off from the University of Rostock and the company PATTERN EXPERT, and was founded in 2007 with support of venture capital.
Experiences, technological input. NeuroProof performs its screening services in its laboratory. In a five year project granted by the state government of Mecklenburg-Vorpommern and the EU, the founders of NeuroProof have established unique experiment protocols and SOPs, so that microelectrode array MEA-neurochip data can be analyzed with pattern recognition methods. NeuroProof computes more than 200 spike train parameters for the induced activity patterns of a whole cultured neuronal network and has developed a database of screened substances. Substances can be compared to this database with respect to similarity of generated activity patterns.
Principal scientific personnel involved:
Dr. Olaf Schröder (mathematician), Dr. Christiane Teichmann (biologist), Konstantin Jügelt (neurobiologist
Role of the participant in the project and main tasks:
Establishing of database structure within WP1 and design of experiments.
NeuroProof performs data analysis of neurotoxicity in vitro experiments and develops parameters for characterizing neurotoxic effects. Pattern recognition methods for classifying neurotoxic substances will be established. Isobolographic analyses are performed in comllaboration with P19 to detect synergistic or antagonistic effects of drug combinations (WP 2.3.).